Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

TAK

$20.880.14%-0.03

Dopo l'orario di chiusura: 20.74-0.14 -0.67%

Takeda Pharmaceutical Co Adr (TAK)

Date: O: H: L: C: Vol:

Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK) Stock Price | Live Quotes & Charts | NYSE - Timothy Sykes

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research

SGIOY Stock Price, Quote & News - Syfe

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Zacks Investment Research

Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider - GlobeNewswire Inc.

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.

AI in Drug Discovery Market Poised for Rapid Growth Through 2035, Fueled by Faster R&D, Precision Medicine and Rising Biopharma Investment - GlobeNewswire Inc.

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - GlobeNewswire Inc.

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.

Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.

Takeda stock advances after U.S. FDA clears MIMRYLO cancer drug - AD HOC NEWS

Protagonist Therapeutics receives FDA approval for polycythemia vera drug - Investing.com

Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - valueresearchonline.com

Takeda Pharmaceutical Co Ltd (ADR) (TAK) News, Articles, Events & Latest Updates - Stocktwits

Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media

Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com

US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com

Takeda Pharmaceutical (TAK) Slips 0.93% to $17.09 as Defensive Sector Shows Mixed Tone - Block Trade Flow - vinanet.vn

Corporate Lobbying Dashboard - Quiver Quantitative

Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.

Takeda Pharmaceutical (TAK) Gains 2.5%; Approaches Key Resistance Level - BPI Bull Correction - vinanet.vn

Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes - GlobeNewswire Inc.

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.

Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada

Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com

Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Nigeria

6 High-Yield International Dividend Stocks Analysts Love - Forbes

ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

TAK - Takeda Pharmaceutical Co ADR Options - Finviz

TAK - Takeda Pharmaceutical Co ADR Options - Finviz

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

TAK - Takeda Pharmaceutical Co ADR Options - Finviz

TAK - Takeda Pharmaceutical Co ADR Options - Finviz

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

TAK - Takeda Pharmaceutical Co ADR Options - Finviz

TAK - Takeda Pharmaceutical Co ADR Options - Finviz

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research

TAK - Takeda Pharmaceutical Co ADR Latest SEC Filings - Finviz

0A87 Forecast — Price Target — Prediction for 2027 - TradingView

TAK-755 from Takeda Pharmaceutical Co. - enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de

Simile a TAK

TEVA$40.703.30%

UTHR$595.670.51%

VTRS$18.681.89%

NBIX$145.340.52%